Version 1
: Received: 7 November 2022 / Approved: 9 November 2022 / Online: 9 November 2022 (11:51:21 CET)
How to cite:
Pavelic, A.; Wöber, C.; Riederer, F.; Zebenholzer, K. Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data. Preprints2022, 2022110177. https://doi.org/10.20944/preprints202211.0177.v1
Pavelic, A.; Wöber, C.; Riederer, F.; Zebenholzer, K. Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data. Preprints 2022, 2022110177. https://doi.org/10.20944/preprints202211.0177.v1
Pavelic, A.; Wöber, C.; Riederer, F.; Zebenholzer, K. Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data. Preprints2022, 2022110177. https://doi.org/10.20944/preprints202211.0177.v1
APA Style
Pavelic, A., Wöber, C., Riederer, F., & Zebenholzer, K. (2022). Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data. Preprints. https://doi.org/10.20944/preprints202211.0177.v1
Chicago/Turabian Style
Pavelic, A., Franz Riederer and Karin Zebenholzer. 2022 "Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data" Preprints. https://doi.org/10.20944/preprints202211.0177.v1
Abstract
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of Erenumab, Galcanezumab, Fremanezumab, or Eptinezumab in patients with migraine. Results: We identified 104 publications (73 retrospective), comprising 8 pharmaco-epidemiologic and 63 clinic-based studies, 30 case reports and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbss. Effectiveness, reported in 59 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 70 papers including 22 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-up of patients treated with anti-CGRP-mAbs.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
